ADAP Adaptimmune Therapeutics plc

1.63
+0.17  (+12%)
Previous Close 1.46
Open 1.45
Price To Book 0.92
Market Cap 171,357,243
Shares 105,127,143
Volume 322,424
Short Ratio
Av. Daily Volume 297,771

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 update due 2H 2019.
MAGE-A4 (ADP-A2M4)
Soild tumors
Phase 1 update due 1H 2020.
AFP (ADP-A2AFP)
Hepatocellular carcinoma
Phase 1 data May 6, 2019 noted 4/7 stable disease. No partial responses. Update due 2H 2019.
MAGE-A10 (ADP-A2M10)
Non-Small Cell Lung Cancer (NSCLC)
Phase 2 trial to be initiated later in 2019.
MAGE-A4 (SPEARHEAD‑1)
Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)
Phase 1 trial initiation announced July 18, 2019 with data due in 2020.
MAGE-A4 (ADP-A2M4CD8 - SURPASS)
Soild tumors

Latest News

  1. What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
  2. Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT
  3. Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript
  4. New Executive Team Announced at Adaptimmune
  5. Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
  6. Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
  7. Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
  8. Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
  9. How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay?
  10. Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
  11. Athenex (ATNX) in Focus: Stock Moves 6.5% Higher
  12. Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why
  13. Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds?
  14. Hedge Funds Piled Into This Stock Right Before Its 40% Ascend
  15. Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
  16. Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It
  17. AdaptImmune partners to advance promising cancer immunotherapies
  18. Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
  19. Adaptimmune Reports First Quarter 2019 Financial Results
  20. Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors